Adial Pharmaceuticals, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-05$6.50 RISE2026-05-14$1.36 PEAK2026-05-28$2.53 143d | -79.1% 129d | Missed | Missed | — | — | +86.0% 14d | Missed |
DROP2025-05-20$18.25 RISE2025-09-29$8.25 PEAK2025-10-09$10.50 142d | -54.8% 132d | Missed | Missed | — | — | +27.3% 10d | Missed |
DROP2025-05-20$18.25 RISE2025-09-25$8.25 PEAK2025-10-09$10.50 142d | -54.8% 128d | Missed | Missed | — | — | +27.3% 14d | Missed |
DROP2025-02-25$23.00 RISE2025-06-24$5.75 PEAK2025-07-28$15.75 153d | -75.0% 119d | Missed | Missed | — | — | +173.9% 34d | Missed |
DROP2024-12-09$30.75 RISE2025-04-04$15.75 PEAK2025-05-01$19.50 143d | -48.8% 116d | Missed | Missed | — | — | +23.8% 27d | Missed |
DROP2024-12-09$30.75 RISE2025-03-31$15.75 PEAK2025-05-01$19.50 143d | -48.8% 112d | Missed | Missed | — | — | +23.8% 31d | Missed |
DROP2024-12-09$30.75 RISE2025-03-11$15.75 PEAK2025-05-01$19.50 143d | -48.8% 92d | Missed | Missed | — | — | +23.8% 51d | Missed |
DROP2024-07-23$32.75 RISE2024-11-27$24.75 PEAK2024-12-09$30.75 139d | -24.4% 127d | Missed | Missed | — | — | +24.2% 12d | Missed |
DROP2024-06-11$33.75 RISE2024-10-15$23.75 PEAK2024-12-09$30.75 181d | -29.6% 126d | Missed | Missed | — | — | +29.5% 55d | Missed |
DROP2024-06-04$34.00 RISE2024-10-11$23.75 PEAK2024-12-09$30.75 188d | -30.1% 129d | Missed | Missed | — | — | +29.5% 59d | Missed |
DROP2024-06-04$34.00 RISE2024-10-10$23.75 PEAK2024-12-09$30.75 188d | -30.1% 128d | Missed | Missed | — | — | +29.5% 60d | Missed |
DROP2024-05-31$36.25 RISE2024-10-09$23.75 PEAK2024-12-09$30.75 192d | -34.5% 131d | Missed | Missed | — | — | +29.5% 61d | Missed |
DROP2024-05-31$36.25 RISE2024-10-08$23.75 PEAK2024-12-09$30.75 192d | -34.5% 130d | Missed | Missed | — | — | +29.5% 62d | Missed |
DROP2024-05-31$36.25 RISE2024-10-02$23.75 PEAK2024-12-09$30.75 192d | -34.5% 124d | Missed | Missed | — | — | +29.5% 68d | Missed |
DROP2024-04-11$74.50 RISE2024-08-05$23.75 PEAK2024-10-22$29.25 194d | -68.1% 116d | Missed | Missed | — | — | +23.2% 78d | Missed |
1–15 / 35 1 / 3 | |||||||
No scored news yet for a sentiment trend.
GLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2026 first quarter ended March 31, 2026. “We are very encouraged by the continued progress we have made in early 2026 to advance AD04 toward late-stage develop
Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(1.48) per share which beat the analyst consensus estimate of $(2.73) by 45.79 percent. This is a 82.59 percent increase over losses of $(8.50) per share
New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial’s precision-medicine approachGLEN ALLEN, Va., April 29, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the filing of a new U.S. utility a
Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04’s role in providing a treatment option for patients where existing treatments inadequately address patient outcomesGLEN ALLEN, Va., April 27, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related dis
Demonstration batch production achieves all prespecified test specifications for dissolution, content uniformity, blend uniformity meeting regulatory requirements to start clinical drug product productionGLEN ALLEN, Va., April 22, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the successful comp
Adial Pharmaceuticals completes AD04 demo batch, validating process transfer and enabling Phase 3 production and FDA IND updates.
H.R. 7091 Supports Development of Investigational Treatments for Alcohol Use Disorder and Aligns with Evolving Federal Recovery StandardsGLEN ALLEN, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and related disorders, today commended members of the U.S. Congress for introducing H.R. 7091, the Expanding Veterans’ Access to Emerging Trea
Adial backs H.R. 7091 targeting AUD in veterans, spotlighting harm reduction therapies and expanding research beyond abstinence-based care.
GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2025 fiscal year ended December 31, 2025. Key Highlights: Regulatory Progress: Achieved positive clinical study results from the AD04-103 pharmacokinetics (P
Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(11.48) per share which missed the analyst consensus estimate of $(0.09) by 12655.56 percent. This is a 206.13 percent decrease over losses of $(3.75) per
The Collaboration Framework marks Adial’s first step towards commercial partnership and establishing an exclusive European pathway as AD04 advances toward pivotal Phase 3 developmentGLEN ALLEN, Va., March 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and related disorders, today announced it has entered into a collaboration framework agreement wi
Adial Pharma signs Europe deal with Molteni for AD04, eyeing up to $60 million in milestones and royalties.
Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3GLEN ALLEN, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq on February 23, 2026, that the Company has regained compliance with the minimum bid price requiremen
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ADIL | +54.84% | -2.83% | -56.36% | -86.09% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +51.87% | +2.88% | -52.92% | -98.78% |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-08 | -2.25 | -1.48 | +34.22% |
| 2026-03-05 | -2.13 | -11.48 | -438.97% |
| 2025-11-13 | -3.50 | -2.00 | +42.86% |
| 2025-08-13 | -5.50 | -4.50 | +18.18% |
| 2025-05-14 | -12.37 | -8.50 | +31.31% |
| 2025-03-04 | -8.25 | -3.75 | +54.55% |
| 2024-11-13 | -11.00 | -9.50 | +13.64% |
| 2024-08-13 | -9.75 | -14.75 | -51.28% |
| 2024-05-14 | -13.62 | -17.03 | -24.99% |
| 2024-04-01 | -19.00 | -9.25 | +51.32% |
| 2023-11-14 | -28.37 | -28.50 | -0.44% |
| 2023-08-21 | -56.25 | -33.25 | +40.89% |
| 2023-05-12 | -87.50 | -68.75 | +21.43% |
| 2023-03-30 | -95.83 | -68.75 | +28.26% |
| 2022-11-14 | -112.50 | -75.00 | +33.33% |
| 2022-08-15 | -91.67 | -100.00 | -9.09% |